Description
A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies’ (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China’s human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.
View Full Report at: http://www.marketresearchreports.biz/analysis/255822
Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.
However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume. Moreover, private and foreign brands hold a dominant position in the markets of Haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, and influenza vaccine, together making up 91.9%, 83.6%, 86.5%, and 69.5% in terms of lot release volume in 2014.
Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/255822
Being bullish about China’s demand for human vaccines and exports, many vaccine producers scale up efforts in vaccine R&D or expand capacity, such as Walvax Biotechnology. By early 2015, GMP on-site certification had been carried out for the company’s Diphtheria-tetanus-acellular pertussis combined vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and DTaP/Hib had made their way into clinical trials; the company is applying registration for meningococcal polysaccharide vaccine (Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru, Thailand, and India.
Table of Content
1 Overview of Vaccine Industry
1.1 Definition and Classification
1.2 Industry Chain
2 Overview of China Human Vaccine Industry & Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.3 Status Quo
2.4 Supply & Demand
2.5 Competitive Landscape
2.6 Developments
2.7 Sales Channel
Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.
Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E:
[email protected]